Kissei broadens biosimilar ambitions through Alteogen alliance
This article was originally published in Scrip
Executive Summary
The mid-sized Japanese pharmaceutical firm Kissei is expanding its interests in biosimilars through a new collaboration with the South Korean venture Alteogen.